<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Springerplus</journal-id><journal-id journal-id-type="iso-abbrev">Springerplus</journal-id><journal-title-group><journal-title>SpringerPlus</journal-title></journal-title-group><issn pub-type="epub">2193-1801</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27652041</article-id><article-id pub-id-type="pmc">5007233</article-id><article-id pub-id-type="publisher-id">3136</article-id><article-id pub-id-type="doi">10.1186/s40064-016-3136-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Clinical re-evaluation of removing blood stasis therapy in treating acute intracerebral hemorrhage safety and efficacy: a protocol for a randomized, controlled, multicenter study (CRRICH Trial)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7023-3481</contrib-id><name><surname>Zeng</surname><given-names>Liling</given-names></name><address><email>541140859@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Guo</surname><given-names>Jianwen</given-names></name><address><email>306247680@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jing</given-names></name><address><email>1003757907@qq.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qixin</given-names></name><address><email>446763061@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Haijun</given-names></name><address><email>278708848@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Rongming</given-names></name><address><email>541140859@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>No. 1 Neurology Department, The 2nd Teaching Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincal Hospital of Chinese Medicine, Guangdong Province Key Laboratory of Emergency medicine of TCM., 111 Da&#x02019;de Road, Yuexiu District, Guangzhou, Guangdong China </aff><aff id="Aff2"><label>2</label>Neurology Department, Shenzhen Longhua New District Center Hospita, Shenzhen, China </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>1466</elocation-id><history><date date-type="received"><day>22</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p> Hypertensive intracerebral hemorrhage (HICH) is one of the most devastating forms of stroke. Currently, no specific therapies for HICH except general medical care. However, in China, medicine of promoting blood circulation (PBC) and removing blood stasis (RBS) are widely and efficiently used to treat HICH and become a potentially effective treatment for the secondary effects of HICH to alleviate brain injury, accelerate neuronal recovery, and improve the prognosis. In order to evaluate the safety and effect of PBC and RBS herbal drugs, we design a prospective, randomized, open, double-blind controlled clinical trial on the hematoma enlargement in HICH patients treating with PBC and RBS herbal medicine within 6&#x000a0;h time window from the symptom onset.</p></sec><sec><title>Methods/design</title><p>A multicenter, three-group, prospective, randomized, double-blinded and placebo-controlled clinical trial. Patients aged 18 or older with HICH confirmed by CT scan within 6&#x000a0;h from the onset are included. 360 patients will be randomized to 3 groups (PBC &#x00026; RBS &#x00026; Placebo) within 6&#x000a0;h of ictus. Stratified block randomization&#x000a0;is undertaken using a sequentially&#x000a0;numbered and opaque envelope. All subjects must take medicine within 6&#x000a0;h of ictus and have another CT scan at about 24&#x000a0;h to confirm hematoma expansion. A postal questionnaire to the patients to evaluate their recorvery at 3&#x000a0;months. Primary outcome is the percent change in the volume of&#x000a0;hematoma at 24&#x000a0;h. Secondary outcomes include: mortality, disability, serious adverse events, etc.</p></sec><sec><title>Conclusions</title><p>The CRRICH Trial is expected to confirm the safety and effect of acute intracerebral hemorrhage treated within 6&#x000a0;h of ictus with &#x0201c;RBS&#x0201d; therapy and to determine whether the traditional therapy can cause hematoma growth after intracerebral hemorrhage.</p></sec><sec><title>Discussions</title><p>This is the first&#x000a0; prospective, multicenter, randomized, placebo-controlled clinical trial to investigate herbal medicine whether&#x000a0;can induce the incidence of hematoma enlargement of AICH patient within the 6 h time window from onset. We need the data to keep the herbal clinical usage safety. </p><p><italic>Trial registration</italic> clinicaltrials.gov: NCT01918722</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Intracerebral hemorrhage</kwd><kwd>Clinical trial</kwd><kwd>Traditional Chinese medicine</kwd><kwd>Promoting blood circulation</kwd><kwd>Removing blood stasis</kwd></kwd-group><funding-group><award-group><funding-source><institution>State Administration of Traditional Chinese Medicine of the P.R.C (SATCM )</institution></funding-source><award-id>ZDJX2012074</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Jianwen</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>HICH is one of the most devastating forms of stroke which is a main cause of death and disability around the world (Roach et al. <xref ref-type="bibr" rid="CR17">2005</xref>), playing&#x000a0;a&#x000a0;significant&#x000a0;part&#x000a0;in morbidity and mortality worldwide (Qureshi et al. <xref ref-type="bibr" rid="CR16">2009</xref>). The&#x000a0;proportion&#x000a0;of patients with ICH who died within 30&#x000a0;days has risen to nearly 40&#x000a0;%, and most of the survivors cannot make a&#x000a0;full&#x000a0;recovery (Qureshi et al. <xref ref-type="bibr" rid="CR16">2009</xref>; van Asch et al. <xref ref-type="bibr" rid="CR18">2010</xref>). Approximately two-third of ICH patients suffer hematoma enlargement within 24&#x000a0;h of ictus (Lim et al. <xref ref-type="bibr" rid="CR11">2008</xref>). Moreover, hematoma growth is an independent&#x000a0;prognostic&#x000a0;determinant (Davis et al. <xref ref-type="bibr" rid="CR2">2006</xref>). Several reasons may be related to the hematoma enlargement in the early stage of ICH, including high blood pressure, &#x0201c;spot&#x0201d; sign of CT scan, sex, age, time window, anticoagulation drugs (Lim et al. <xref ref-type="bibr" rid="CR11">2008</xref>). But so far there have not been specific therapies or treatments preventing hematoma expansion and improve the outcome after ICH. Furthermore, it&#x000a0;has&#x000a0;been&#x000a0;confirmed that&#x000a0;neither mini-traumatic&#x000a0;operation nor&#x000a0;the present accessible medicine is proved to be the ideal treatment based on the available&#x000a0;evidence-based&#x000a0;medical&#x000a0;researches (Morgenstern et al. <xref ref-type="bibr" rid="CR15">2010</xref>; Mendelow et al. <xref ref-type="bibr" rid="CR14">2013</xref>; Mayer et al. <xref ref-type="bibr" rid="CR13">2008</xref>).</p><p>Faced with the limitations of the current available therapies, herbal medicine of promoting blood circulation (PBC) and removing blood stasis (RBS) are widely and efficiently used in Chinese hospitals to treat HICH based on the TCM theory of &#x02018;the blood flow outside the vessels is the blood stasis&#x02019;. However, whether these herbal medicine can cause hematoma enlargement leading to serious&#x000a0;adverse&#x000a0;events is undefined until now (Li et al. <xref ref-type="bibr" rid="CR10">2015</xref>).</p><p>In order to evaluate the safety of PBC and RBS herbal drugs, we design a prospective, randomized, open, double-blind controlled clinical trial on the hematoma enlargement in HICH patients treating with PBC and RBS herbal medicine within 6&#x000a0;h time window from the symptom onset.</p></sec><sec id="Sec2"><title>Study design and methods</title><sec id="Sec3"><title>Objective</title><p> The aim of this study is to evaluate the safety and effect of acute intracerebral hemorrhage (AICH) treated with &#x0201c;RBS&#x0201d; therapy and to determine whether the traditional therapy can cause hematoma growth after intracerebral hemorrhage.</p></sec><sec id="Sec4"><title>Centre eligibility</title><p>There are 13 centers included from all over&#x000a0;China. Only hospitals that have been experienced in clinical trial and previously abided by trial guidelines well are qualified to be research centers.</p></sec><sec id="Sec5"><title>Design</title><p>A multicenter, three-group, prospective, randomized, double-blinded and placebo-controlled clinical trial. The study patient flow diagram is displayed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Study design diagram. <italic>CT</italic> computed tomography, <italic>CTA</italic> computed tomography angiography, <italic>NIHSS</italic> National Institutes of Health Stroke Scale, <italic>mRS</italic> modified Rankin Scale, <italic>BI</italic> Barthel Index, <italic>GCS</italic> Glasgow Coma Scale</p></caption><graphic xlink:href="40064_2016_3136_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec6"><title>Patient population</title><p>Entry criteria will be structured to enroll patients aged 18 or older with ICH confirmed by CT scan within 6&#x000a0;h after the onset. The exclusion criteria are surgical evacuation of hematoma planned within 24&#x000a0;h after the onset and secondary intracerebral hemorrhage. More&#x000a0;detailed&#x000a0;description of the study inclusion and exclusion criteria can be gotten in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Study inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">
<italic>Inclusion criteria</italic>
</td></tr><tr><td align="left">Ages eligible for study: 18&#x000a0;years or older</td></tr><tr><td align="left">Genders eligible for study: both</td></tr><tr><td align="left">AICH confirmed by craniocerebral CT scan</td></tr><tr><td align="left">Within 6&#x000a0;h after the onset of symptom</td></tr><tr><td align="left">GCS&#x000a0;&#x02265;&#x000a0;6</td></tr><tr><td align="left">Sign the informed consent form</td></tr><tr><td align="left">
<italic>Exclusion criteria</italic>
</td></tr><tr><td align="left">Secondary intracerebral hemorrhage resulting from trauma, brain tumor, blood diseases, arteriovenous malformation or aneurysm, etc.</td></tr><tr><td align="left">Patients with severe heart, liver&#x000a0;or&#x000a0;kidney disease</td></tr><tr><td align="left">Intolerance to herbal medicine</td></tr><tr><td align="left">Patients&#x000a0;with&#x000a0;allergies</td></tr><tr><td align="left">Patients planning a surgical evacuation of hematoma with severe cerebral hernia at&#x000a0;super-early&#x000a0;stage</td></tr><tr><td align="left">Patients with poor compliance</td></tr></tbody></table><table-wrap-foot><p>At screening, this criteria start. <italic>CT</italic> computed tomography, <italic>GCS</italic> Glasgow Coma Scale, <italic>TCM</italic> Traditional Chinese Medicine, <italic>AICH</italic> acute intracerebral hemorrhage</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>Randomization</title><p>We define the herbal medicine as PBC or RBS under the criteria of Chinese Pharmacopoeia of 2010 version. The combined herbal drugs, such as relieving heat and calming liver Yang, decreasing wind and dispersing phlegm, loosing the bowels, are also under the criteria of Chinese Pharmacopoeia of 2010 version. Within 6&#x000a0;h from the onset, participants will be assigned&#x000a0;at random to one of three treatment groups with a ratio of 1:1:1: (1) Group A: RBS, stasis-breaking herbal medicine (8 herbals); (2) Group B: PBC, herbal medicine without stasis-breaking herbal medicine (6 herbals) and (3) Group C: placebo comparator, only placebo. Randomization is generated and stratified in blocks of six by PROC PLAN process using the SAS software version 9.13. Stratified block randomization&#x000a0;is concealed using a sequentially&#x000a0;numbered and opaque envelope. The number of each group will be in balance within research centers and by the baseline NIHSS severity (&#x02264;17 vs. &#x0003e;17), age (&#x0003e;18&#x000a0;years) and hemorrhagic location (basal ganglia vs. all other), patients&#x02019; sex, baseline Glasgow Coma Scale, duration from onset to the first CT scan.</p></sec><sec id="Sec8"><title>Intervention</title><sec id="Sec9"><title>Treatment</title><p>The interventions in each group are listed in the Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Treatment is administered within 6&#x000a0;h after the onset. The experimental drugs are given as powder prepared by Kangyuan Pharamaceutical factory according to a Good Manufacture Practice (GMP). Each unit of TCM medicine or placebo is dissolved&#x000a0;into&#x000a0;solution in a cup&#x000a0;of&#x000a0;boiling water of 200&#x000a0;ml. Each patient orally takes 200&#x000a0;ml two times daily for 10&#x000a0;days. And the placebo medicine is provided according to the same standardized method. Quality control is enforced strictly throughout the trial.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Groups and interventions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Groups</th><th align="left">Interventions</th><th align="left">Signa</th></tr></thead><tbody><tr><td align="left">RBS</td><td align="left">8 herbals [with 2 herbals of RBS (<italic>Hirudo</italic> and <italic>Tabanus</italic>), as well as herbals of PBC and other combined herbals]</td><td align="left">One dose, bid, by oral or nasogastric tube for 10&#x000a0;days</td></tr><tr><td align="left">PBC</td><td align="left">6 herbals (remove 2 herbals of RBS, left with PBC and other combined herbals)</td><td align="left">One dose, bid, by oral or nasogastric tube for 10&#x000a0;days</td></tr><tr><td align="left">Placebo comparator</td><td align="left">Placebo herbal medicine (with dextrin, farina and so on)</td><td align="left">One dose, bid, by oral or nasogastric tube for 10&#x000a0;days</td></tr></tbody></table><table-wrap-foot><p>
<italic>RBS</italic> removing blood stasis, <italic>PBC</italic> promoting blood circulation</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec10"><title>CT scanning</title><p>At screening, the baseline CT scans are obtained immediately after arriving at treating hospital to identify intracerebral hemorrhage; the first follow-up CT scans are done at 24&#x000a0;h after the onset of symptoms (range 21&#x02013;27) to assess hematoma growth; and the second follow-up CT scans are performed on 10&#x000a0;days (range 8&#x02013;14) after drug administration. The hematoma volume is measured by ABC/2 Coniglobus formula (Kothari et al. <xref ref-type="bibr" rid="CR8">1996</xref>). Hematoma growth is operationally defined as an increase in the hematoma volume of &#x0003e;33&#x000a0;% as measured by image analysis on the 24&#x000a0;h CT in comparison with the baseline CT scan (Kothari et al. <xref ref-type="bibr" rid="CR8">1996</xref>) (if the first follow-up CT scan cannot be done within 24&#x000a0;h from the onset, a 48-h CT scan will be analyzed). Blinding&#x000a0;for the two neuroradiologists is&#x000a0;maintained&#x000a0;through analyzation&#x000a0;of digital CT data. Computerized planimetric techniques are used to calculate the hematoma volume to valuated the primary end point. In&#x000a0;a&#x000a0;previous&#x000a0;study, the interobserver&#x000a0;agreement&#x000a0;of this method has been proven perfect (Xu et al. <xref ref-type="bibr" rid="CR21">2015</xref>).</p></sec><sec id="Sec11"><title>Follow-up and outcome&#x000a0;evaluation</title><p>Clinical assessments are performed at enrollment; at 24&#x000a0;h after the onset of symptoms; on the&#x000a0;10th&#x000a0;day after admission; and on the&#x000a0;90th&#x000a0;day after the stroke. During the&#x000a0;follow-up&#x000a0;period, the following&#x000a0;scales will used:the GCS assessing the level&#x000a0;of&#x000a0;consciousness according to the score ranging from 15 (normal) to 3 (deep coma);the NIHSS measuring neurologic deficit according to the score ranging from 0 (normal) to 42 (coma with quadriplegia), the mRS evaluating functional independence, the BI assessing the ability&#x000a0;of&#x000a0;daily&#x000a0;life. More detailed information about the schedule of study visits is&#x000a0;shown&#x000a0;in&#x000a0;Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Study visits</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Assessment method</th><th align="left">Screening</th><th align="left">Onset (0&#x000a0;h)</th><th align="left">24&#x000a0;h</th><th align="left">10&#x02013;14&#x000a0;days</th><th align="left">90-day follow-up</th></tr></thead><tbody><tr><td align="left">Patient population</td><td align="left">W</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">History</td><td align="left">W</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Physical examination</td><td align="left">W</td><td align="left">W</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">CT/CTA</td><td align="left">W</td><td align="left"/><td align="left">W</td><td align="left">W</td><td align="left">&#x02013;</td></tr><tr><td align="left">Confirmation of entry criteria</td><td align="left">W</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Signing consent form</td><td align="left">W</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Serum and urine test</td><td align="left">W</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Concomitant medication or treatment</td><td align="left">W</td><td align="left">W</td><td align="left">W</td><td align="left">W</td><td align="left">W</td></tr><tr><td align="left">GCS</td><td align="left">W</td><td align="left">W</td><td align="left">W</td><td align="left">W</td><td align="left">&#x02013;</td></tr><tr><td align="left">NIHSS</td><td align="left">W</td><td align="left">W</td><td align="left">W</td><td align="left">W</td><td align="left">W</td></tr><tr><td align="left">BI</td><td align="left">W</td><td align="left"/><td align="left">&#x02013;</td><td align="left">W</td><td align="left">W</td></tr><tr><td align="left">mRS</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">W</td><td align="left">W</td></tr><tr><td align="left">Adverse events</td><td align="left">w</td><td align="left">w</td><td align="left">w</td><td align="left">w</td><td align="left">W</td></tr><tr><td align="left">Summary of patient</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">W</td></tr></tbody></table><table-wrap-foot><p>
<italic>CT</italic> computed tomography, <italic>CTA</italic> computed tomography angiography, <italic>NIHSS</italic> National Institutes of Health Stroke Scale, <italic>mRS</italic> modified Rankin Scale, <italic>BI</italic> Barthel Index, <italic>GCS</italic> Glasgow Coma Scale</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Adverse event validation</title><p>All adverse events will be recorded during&#x000a0;the stay&#x000a0;in hospital and all serious adverse events will be recorded 90&#x000a0;days&#x000a0;after&#x000a0;onset. Clinical events committee, which are composed&#x000a0;of four expert physicians independent of the research centers, will validate all adverse events. Relatedness categories are as follows: (1) primary disease-related: events obviously due to primary disease with no time relationship to the therapy, or medication. (2) concomitant disease-related: events due to diseases instead of the primary disease with no time relationship to therapy or medication; (3) TCM medicine-related: events obviously due to TCM medicine with no time relationship to other therapy;(4) medicine unknown: medicine related but unable to attribute a specific medicine; (5) individual difference-related: events have strong time relationship to individual constitution, whose allergic constitution are intolerant to traditional Chinese medicine (TCM); (6) other; and (7) unknown.</p></sec><sec id="Sec13"><title>Primary outcome</title><p>The primary end-point measure is the percent&#x000a0;change in the hematoma volume measured by ABC/2 Coniglobus formula (Kothari et al. <xref ref-type="bibr" rid="CR8">1996</xref>) at the 24th hour after the onset. Hematoma growth is operationally defined as an increase in the hematoma volume of &#x0003e;33&#x000a0;% as measured by image analysis on the 24&#x000a0;h CT compared with the baseline CT scan.</p></sec><sec id="Sec14"><title>Secondary outcomes</title><p>Three secondary clinical efficacy outcomes are included as follows: (1) death owing to any cause on the 14th day; (2) disability as defined by mRS score &#x02264;2 on the 90th day; and (3) change in NIHSS score at the 24th hour after the onset of symptoms.</p><p>In the study two technical efficacy outcomes are included as follows: (1) volume of hematoma growth as measured by a CT scan at 24&#x000a0;&#x000b1;&#x000a0;3&#x000a0;h after onset of symptoms compared with the baseline CT scan; (2) recurrent bleeding measured by CT scan on 10&#x000a0;days after drug administration.</p><p>Two study safety outcomes are included as follows: (1) all serious adverse events; (2)hematoma growth at 24&#x000a0;&#x000b1;&#x000a0;3&#x000a0;h.</p></sec><sec id="Sec15"><title>Blinding</title><p>Before&#x000a0;the&#x000a0;code is broken following receipt of e-mail&#x000a0;notification&#x000a0;of&#x000a0;the&#x000a0;completion&#x000a0;of&#x000a0;the study, the persons&#x000a0;involved in the research including the investigators, subjects and the data&#x000a0;analysts&#x000a0;are blinded to the interventions and outcomes. Only the&#x000a0;data&#x000a0;administrators are&#x000a0;permitted&#x000a0;access&#x000a0;to unblinded data.</p></sec></sec><sec id="Sec16"><title>Statistical considerations</title><sec id="Sec17"><title>Sample size</title><p>The primary efficacy outcome is the percent&#x000a0;change in the volume of hematoma at the 24th hour after onset in the two treatment groups as compared with the placebo group, assessed via the blinded measurement of hematoma by ABC/2 Coniglobus formula. The statistical hypothesis on the percentage of hematoma expansion is that the relative hematoma volume in subjects of three groups are the same to each other. Power and sample size are determined using relative hematoma volume at 24&#x000a0;h as the main outcome variable. According to the previous literature (Huang et al. <xref ref-type="bibr" rid="CR6">2010</xref>; Wang et al. <xref ref-type="bibr" rid="CR19">2013</xref>; He et al. <xref ref-type="bibr" rid="CR5">2002</xref>), the true proportions of subjects in 3 groups with different rations of hematoma expansion at 24&#x000a0;h are presented in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. In this case, the <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\upgamma$$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:math><inline-graphic xlink:href="40064_2016_3136_Article_IEq1.gif"/></alternatives></inline-formula> is 12.65, <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\uppi\_\hbox{max}$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mi mathvariant="normal">&#x003c0;</mml:mi><mml:mi>_</mml:mi><mml:mtext>max</mml:mtext></mml:mrow></mml:math><inline-graphic xlink:href="40064_2016_3136_Article_IEq2.gif"/></alternatives></inline-formula> 38&#x000a0;% and <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\uppi\_\hbox{min}$$\end{document}</tex-math><mml:math id="M6"><mml:mrow><mml:mi mathvariant="normal">&#x003c0;</mml:mi><mml:mi>_</mml:mi><mml:mtext>min</mml:mtext></mml:mrow></mml:math><inline-graphic xlink:href="40064_2016_3136_Article_IEq3.gif"/></alternatives></inline-formula> 7&#x000a0;%. With a two-sided alpha level at 0.05, 285 participants finishing&#x000a0;the final&#x000a0;follow up provide 90&#x000a0;% power to&#x000a0;test&#x000a0;the&#x000a0;hypothesis&#x000a0;of the study&#x02019;s primary effectiveness, which is calculated by&#x000a0;the following&#x000a0;formula; assuming that the non-investigation rate of the primary outcomes is 20&#x000a0;%, 360 participants will be needed.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Hypothesized true outcomes for sample size calculations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Randomized group</th><th align="left">PBC</th><th align="left">RBS</th><th align="left">Placebo</th></tr></thead><tbody><tr><td align="left">Percentage of change</td><td char="." align="char">7</td><td char="." align="char">16</td><td char="." align="char">38</td></tr></tbody></table><table-wrap-foot><p>
<italic>RBS</italic> removing blood stasis, <italic>PBC</italic> promoting blood circulation</p></table-wrap-foot></table-wrap><disp-formula id="Equa"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$n = 1641.6\upgamma/((\sin^{ \wedge } ( - 1)\surd (\uppi\_\hbox{max} )) - \sin^{ \wedge } ( - 1)\surd\uppi\_{\rm min}^{ \wedge } 2$$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1641.6</mml:mn><mml:mi mathvariant="normal">&#x003b3;</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mo>sin</mml:mo><mml:mo>&#x02227;</mml:mo></mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>&#x0221a;</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">&#x003c0;</mml:mi><mml:mi>_</mml:mi><mml:mtext>max</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msup><mml:mo>sin</mml:mo><mml:mo>&#x02227;</mml:mo></mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>&#x0221a;</mml:mi><mml:mi mathvariant="normal">&#x003c0;</mml:mi><mml:mi>_</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mo>&#x02227;</mml:mo></mml:msup><mml:mn>2</mml:mn></mml:mrow></mml:math><graphic xlink:href="40064_2016_3136_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec18"><title>Statistical analyses</title><p>All analysis&#x000a0;are by&#x000a0;intention&#x000a0;to treat with a beta level of 0.10 and an alpha level of 0.025 (Type I and Type II error). The primary outcome is the percent&#x000a0;change in the volume of the hematoma measured by a CT scan at 24&#x000a0;&#x000b1;&#x000a0;3&#x000a0;h after the onset compared with the baseline CT scan. The volumes of the hematoma measured by a CT scan will be analyzed using generalized linear mixed models. The subjects and the readers (two neuroradiologists) will be defined as random effects, and the baseline volume of hematoma, the time from the onset to CT scanning, and the time from CT scanning to study intervention will be defined as fixed-effect covariates. The percentages of changes in the volume of hematoma are transformed to normality and eliminate negative values&#x000a0;via logarithmic&#x000a0;transformations. Comparisons will be made between the two treatment groups with placebo using Bonferroni&#x02019;s method with a threshold of significance of 0.0167. The threshold of significance for all other comparisons was 0.05. Subjects died before finishing the follow up will be assigned the worst possible scores for measures of neurologic deficit and function prognosis. Regarding surviving subjects with missing outcome data, the last visit will be carried&#x000a0;down. The scores on mRS will be analyzed in a cumulative logit model, with statistical adjustment for age, the baseline hematoma volume, the site of hemorrhage, and the baseline neurological&#x000a0;status. The scores on the BI and NIHSS will be analyzed with Wilcoxon rank-sum tests. The difference of the frequency of SAE in the three groups at 3&#x000a0;months will be analyzed with Fisher&#x02019;s exact test or the Chi square test. All dates will be analyzed via SPSS software, version 21.0.</p></sec><sec id="Sec19"><title>Lost-to-follow-up and missing data</title><p>It is supposed that there is no missing safety data on SAE, because of the&#x000a0;careful&#x000a0;observation and detailed&#x000a0;records while in hospital. For surviving patients with missing outcome data, the last observation was carried forward. Regarding other incomplete primary outcome data, we will use multiple imputation to&#x000a0;fill in&#x000a0;missing&#x000a0;data with&#x000a0;standard&#x000a0;statistical&#x000a0;procedure.</p></sec><sec id="Sec20"><title>Data and safety monitoring</title><p>The Data Safty Monitoring Committee deliberates the data from intermediate safety analysis report and contacts the Trial Steering Committee. Interim&#x000a0;results are extremely secret and once one of the three groups shows a distinct&#x000a0;advantage&#x000a0;over&#x000a0;others, the committee will counsel to end the study ahead of schedule.</p></sec></sec><sec id="Sec21"><title>Rationale for the design</title><sec id="Sec22"><title>Justification for the choice of three groups</title><p>In the study, we design three groups to verify the better efficacy of combining RBS with PBC herbal medicine based on formula components analysis/methods. As recorded in the Chinese Pharmacopoeia of 2010 version (Chinese Pharmacopoeia Commission <xref ref-type="bibr" rid="CR1">2010</xref>), RBS herbal medicine should be combined with PBC and other herbals correctly in the Traditional Chinese Medicine Formula in order to avoid the rebleeding risk. Some herbal have strong RBS and promoting blood circulation function, for example, <italic>leech</italic> can cause rebleeding (Liu et al. <xref ref-type="bibr" rid="CR12">2012</xref>). Some others have two-way adjustment pharmacological effect, for example, <italic>Radix notoginseng</italic> can not only promote blood circulation but also stop bleeding. Traditionally, the prescription of Chinese medicine to learn is through reasonable compatibility other than a single drug, to eliminate this rebleeding risk.</p></sec><sec id="Sec23"><title>Justification for the choice of the therapeutic time window</title><p>The decision on the time of beginning PBS therapy within 6&#x000a0;h after the onset of symptoms is&#x000a0;made&#x000a0;on&#x000a0;the&#x000a0;basis&#x000a0;of the data from previous studies (Xu et al. <xref ref-type="bibr" rid="CR21">2015</xref>). Among most (83&#x000a0;%) of patients with hematoma growth done the first-time CT scan within 6&#x000a0;h after the onset, enlargement after 24&#x000a0;h of onset happens rarely (Kazui et al. <xref ref-type="bibr" rid="CR7">1996</xref>). So some neurologists show their opinion that PBC and RBS herbal medicine should be used after 24&#x000a0;h of onset in order to prevent rebleeding risk (Wanzhng et al. <xref ref-type="bibr" rid="CR20">2004</xref>). However others support that PBC and RBS herbal medicine should be administrated as sooner as possible (Li <xref ref-type="bibr" rid="CR9">2003</xref>). And furthermore, Guo et al.&#x02019;s (<xref ref-type="bibr" rid="CR4">2005</xref>) previous study did not show deterioration of condition of the AICH patients who were treated with herbal compound within 6&#x000a0;h time window from the onset, suggesting better&#x000a0;curative effect for earlier therapy. This finding might reduce hospital stay, healthcare-related expenses,&#x000a0;as well as complications&#x000a0;and&#x000a0;mortality.</p></sec></sec><sec id="Sec24"><title>Discussion</title><p>Further prospective, multicenter, randomized, placebo control clinical trials are needed to provide better quality evidence, though in a retrospective study (Xu et al. <xref ref-type="bibr" rid="CR21">2015</xref>), we found that PBC and RBS herbal medicine were not associated with an&#x000a0;increased risk&#x000a0;of hematoma growth within 24&#x000a0;h after the onset of symptoms. Meanwhile, a meta-analysis (Li et al. <xref ref-type="bibr" rid="CR10">2015</xref>) which included 9 randomized-controlled clinical trials with 798 individuals showed that PBC and RBS single therapy and combination&#x000a0;therapy for acute ICH could reduce the&#x000a0;volumes of&#x000a0;brain&#x000a0;hematoma&#x000a0;and&#x000a0;cerebral&#x000a0;edema, improve the neural&#x000a0;function and reduce the mortality and disability rate. Moreover, unlike western conventional medication group, fewer adverse&#x000a0;reactions&#x000a0;occurred in herb medicine group. In&#x000a0;spite&#x000a0;of the obviously positive results, It&#x02019;s&#x000a0;too&#x000a0;early&#x000a0;to&#x000a0;draw&#x000a0;conclusion about the efficacy and safety of PBC &#x00026; RBS for ICH since the limitation of the included studies in the meta-analysis. Therefore, high-quality RCTs are needed.</p><p>The CRRICH Trial will provide definitive information on the efficacy and safety of the RBS therapy. The trial is designed to learn lessons from study of earlier conservative therapies that cannot demonstrate the treatment benefit of TCM with RBS rather well. Unlike those prior studies (Fan and Jin <xref ref-type="bibr" rid="CR3">2000</xref>), the trial set three groups (PBS &#x00026; RPS &#x00026; Placebo), better observating the efficacy of RBS or PBS to confirm whether PBC and RBS herbal medicine induce the incidence of hematoma enlargement of AICH patients within the 6&#x000a0;h time window from onset. The shortages of prior studies are as follows: (1) most studies are retrospective, unblinded trials; (2) mixed PBS with RBS; (3) time window from onset is 24&#x000a0;h or later; (4) not multicenter RCT. In order to make up for these limitations, we have designed a prospective, 13 hospitals, randomized, placebo-controlled clinical trial (clinicaltrials.gov: NCT01918722) to confirm if PBC and RBS herbal medicine induce the incidence of hematoma enlargement of AICH patient within the 6&#x000a0;h time window from onset. The trial enrolled its first patient on October 25, 2013. And 280 cases have recruited so far. The study is still ongoing until all 360 patients are completed in December 2016. When completed, we will provide pivotal data allowing.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ICH</term><def><p>intracerebral hemorrhage</p></def></def-item><def-item><term>CT</term><def><p>computed tomography</p></def></def-item><def-item><term>CTA</term><def><p>computed tomography angiography</p></def></def-item><def-item><term>NIHSS</term><def><p>National Institutes of Health Stroke Scale</p></def></def-item><def-item><term>mRS</term><def><p>modified Rankin Scale</p></def></def-item><def-item><term>BI</term><def><p>Barthel Index</p></def></def-item><def-item><term>GCS</term><def><p>Glasgow Coma Scale</p></def></def-item><def-item><term>SATCM</term><def><p>State Administration of Traditional Chinese Medicine of the P.R.C.</p></def></def-item><def-item><term>TCM</term><def><p>traditional Chinese medicine</p></def></def-item><def-item><term>RBS</term><def><p>removing blood stasis</p></def></def-item><def-item><term>PBC</term><def><p>promoting blood circulation</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>JG is &#x000a0;the PI of the Clinical trial (CRRICH Trial). He designed the trial, perform the trial, control the quality, and process the data. The manuscript was also modified by JG. LZ, JG and JW are in&#x000a0;charge&#x000a0;of&#x000a0;the conception of the research protocol and study coordination. XZ is responsible for statistical design and statistical analysis throughout the study. HL takes charge of performing and analyzing CT scan, as well as assisting in initial study design. RL takes part in study management. All authors have been participated&#x000a0;in writing the manuscript and have approved it prior to submission for publication. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>The authors thank Professor Zehuai Wen and Dr. Meiling Weng because they directed the statistics design and the date monitoring. Wen is the director of Key Unit of Methodology in Clinical Research of Guangdong Province Hospital of Traditional Chinese Medicine. The authors also thank China National Clinical Study Base Project of Traditional Chinese Medicine, sponsored by State Administration of Traditional Chinese Medicine of the People&#x02019;s Republic of China (Grant No. JDZX2012074).</p></sec><sec id="FPar3"><title>Competing interests</title><p>The study is funded by State Administration of Traditional Chinese Medicine of the P.R.C. (SATCM) and the study protocol has undergone peer-review by the funding body. The authors declare that they have no competing interests.</p></sec><sec id="FPar2"><title>Ethics approval and consent to participate</title><p>Ethics approval for the trial is received&#x000a0;from Institutional Ethics Committee of Guangdong Provincial Hospital of Traditional Hospital (Ethical Review No. B2013-085-01). Recruitment can be begin until after appropriate local ethical approval is obtained from each research center of the trial with proof of the approval forwarded to the trial coordinating office. The study is performed&#x000a0;in accordance with local ethical and Research and Development procedures. Only if the local ethical approval is received from each research center, should recruitment begin. An agreement is signed between the sponsor (Guangdong Provincial Hospital of Traditional Hospital), the holder of the study funding (State Administration of Traditional Chinese Medicine of the P.R.C. (SATCM)) and the research center before initiating the trial at the center.</p></sec><sec id="FPar4"><title>Funding</title><p>State Administration of Traditional Chinese Medicine of the P.R.C. (SATCM) has allocated to Guangdong Provincial Hospital of TCM (GPHTCM): SATCM Grant No: ZDJX2012074. This report is an independent study supported by the SATCM and conducted by the GPHTCM in the name of the SATCM&#x02013;GPHTCM partnership. The viewpoints stated in this essay are those of the authors and may not&#x000a0;be&#x000a0;those of the SATCM, GPHTH or the Public Health Bureau.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Chinese Pharmacopoeia Commission (2010) The pharmacopoeia of the People&#x02019;s Republic of China, vol. 1. Chemical Industry Press, Beijing, pp 141, 260</mixed-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Broderick</surname><given-names>J</given-names></name><name><surname>Hennerici</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage</article-title><source>Neurology</source><year>2006</year><volume>66</volume><issue>8</issue><fpage>1175</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000208408.98482.99</pub-id><pub-id pub-id-type="pmid">16636233</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>MW</given-names></name></person-group><article-title>The influence of Liangxuetongyu oral solution on early rehabilitation of hypertensive cerebral hemorrhage</article-title><source>Chin J Integr Tradit West Med.</source><year>2000</year><volume>20</volume><fpage>138</fpage><lpage>140</lpage></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>Clinical study on the therapeutic time window of acute intracerebral hemorrhage treated with herbal composition of Zhongfengxingnao taken orally</article-title><source>Chin J cerebrovasc Dis</source><year>2005</year><volume>2</volume><issue>6</issue><fpage>255</fpage><lpage>259</lpage></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>QR</given-names></name><name><surname>Zhao</surname><given-names>JX</given-names></name></person-group><article-title>Therapeutic efficacy of Xueshuantong injection on patients with acute intracerebral hemorrhage in early stage</article-title><source>Chin J Integr Tradit West Med Intensive Crit Care</source><year>2002</year><volume>9</volume><fpage>27</fpage><lpage>29</lpage></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>ZP</given-names></name></person-group><article-title>Therapeutic efficacy of stereotactic microsurgery combined with therapy of inducing resuscitation, activating blood and promoting diuresis in treating severe cerebellopontine hemorrhage</article-title><source>J Guangzhou Univ Tradit Chin Med</source><year>2010</year><volume>27</volume><fpage>445</fpage><lpage>448</lpage></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazui</surname><given-names>S</given-names></name><name><surname>Naritomi</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name></person-group><article-title>Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course</article-title><source>Stroke</source><year>1996</year><volume>27</volume><issue>10</issue><fpage>1783</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1161/01.STR.27.10.1783</pub-id><pub-id pub-id-type="pmid">8841330</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothari</surname><given-names>RU</given-names></name><name><surname>Brott</surname><given-names>T</given-names></name><name><surname>Broderick</surname><given-names>JP</given-names></name><etal/></person-group><article-title>The ABCs of measuring intracerebral hemorrhage volumes</article-title><source>Stroke</source><year>1996</year><volume>27</volume><issue>8</issue><fpage>1304</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1161/01.STR.27.8.1304</pub-id><pub-id pub-id-type="pmid">8711791</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Discussion of early use promoting blood circulation and removing blood stasis herbal medicine</article-title><source>Chin J Basic Med Tradit Chin Med</source><year>2003</year><volume>05</volume><fpage>58</fpage><lpage>59</lpage></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HQ</given-names></name><name><surname>Wei</surname><given-names>JJ</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><etal/></person-group><article-title>Promoting blood circulation for removing blood stasis therapy for acute intracerebral hemorrhage: a systematic review and meta-analysis</article-title><source>Acta Pharmacol Sin</source><year>2015</year><volume>36</volume><issue>6</issue><fpage>659</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/aps.2014.139</pub-id><pub-id pub-id-type="pmid">25960132</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JK</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Cho</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Multivariate analysis of risk factors of hematoma expansion in spontaneous intracerebral hemorrhage</article-title><source>Surg Neurol</source><year>2008</year><volume>69</volume><issue>1</issue><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.surneu.2007.07.025</pub-id><pub-id pub-id-type="pmid">18054613</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>JA</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name></person-group><article-title>Taoren&#x02013;Honghua herb pair and its main components promoting blood circulation through influencing on hemorheology, plasma coagulation and platelet aggregation</article-title><source>J Ethnopharmacol</source><year>2012</year><volume>139</volume><issue>2</issue><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.11.016</pub-id><pub-id pub-id-type="pmid">22123200</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>SA</given-names></name><name><surname>Brun</surname><given-names>NC</given-names></name><name><surname>Begtrup</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>20</issue><fpage>2127</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0707534</pub-id><pub-id pub-id-type="pmid">18480205</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendelow</surname><given-names>AD</given-names></name><name><surname>Gregson</surname><given-names>BA</given-names></name><name><surname>Rowan</surname><given-names>EN</given-names></name><name><surname>Murray</surname><given-names>GD</given-names></name><name><surname>Gholkar</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>PM</given-names></name></person-group><article-title>Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial</article-title><source>Lancet</source><year>2013</year><volume>382</volume><issue>9890</issue><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60986-1</pub-id><pub-id pub-id-type="pmid">23726393</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgenstern</surname><given-names>LB</given-names></name><name><surname>Hemphill</surname><given-names>JC</given-names><suffix>3rd</suffix></name><name><surname>Anderson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2010</year><volume>41</volume><issue>9</issue><fpage>2108</fpage><lpage>2129</lpage><pub-id pub-id-type="doi">10.1161/STR.0b013e3181ec611b</pub-id><pub-id pub-id-type="pmid">20651276</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>AI</given-names></name><name><surname>Mendelow</surname><given-names>AD</given-names></name><name><surname>Hanley</surname><given-names>DF</given-names></name></person-group><article-title>Intracerebral haemorrhage</article-title><source>Lancet</source><year>2009</year><volume>373</volume><issue>9675</issue><fpage>1632</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60371-8</pub-id><pub-id pub-id-type="pmid">19427958</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roach</surname><given-names>ESGMR</given-names></name><name><surname>Adams</surname><given-names>RBJ</given-names></name><name><surname>Daniels</surname><given-names>SDG</given-names></name><name><surname>Ferriero</surname><given-names>DJBV</given-names></name><name><surname>Kirkham</surname><given-names>FJSRM</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name></person-group><article-title>Incidence and 10-year survival of intracerebral hemorrhage in a population-based registr</article-title><source>Stroke</source><year>2005</year><volume>36</volume><fpage>934</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000160756.72109.95</pub-id><pub-id pub-id-type="pmid">15790947</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Asch</surname><given-names>CJ</given-names></name><name><surname>Luitse</surname><given-names>MJ</given-names></name><name><surname>Rinkel</surname><given-names>GJ</given-names></name><name><surname>van der Tweel</surname><given-names>I</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><name><surname>Klijn</surname><given-names>CJ</given-names></name></person-group><article-title>Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><issue>2</issue><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70340-0</pub-id><pub-id pub-id-type="pmid">20056489</pub-id></element-citation></ref><ref id="CR19"><mixed-citation publication-type="other">Wang YQ, Shi Q, Wang WP (2013) Clinical study of Xuefuzhuyu decoction on hypertensive intracerebral hemorrhage. J Emerg Tradit Chin Med 22:1686&#x02013;167, 1689 <bold>(Chinese)</bold></mixed-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanzhng</surname><given-names>Y</given-names></name><name><surname>Zhilan</surname><given-names>Z</given-names></name><name><surname>Ming</surname><given-names>Z</given-names></name><etal/></person-group><article-title>once again on bleeding after cerebral hemorrhage and the time window for therapy of &#x0201c;promoting blood circulation and removing blood stasis&#x0201d;</article-title><source>Chin J Integr Med Cardio Cerebrovasc Dis</source><year>2004</year><volume>11</volume><fpage>662</fpage><lpage>665</lpage></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Can herbal medicine cause hematoma enlargement of hypertensive intracerebral hemorrhage within 24 hrs time window? A retrospective study of 256 cases from a single center in China</article-title><source>Evid Based Complement Altern Med</source><year>2015</year><volume>10</volume><issue>8</issue><fpage>1155</fpage><lpage>1158</lpage></element-citation></ref></ref-list></back></article>